Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.[ Read More ]
The intrinsic value of one TLIS stock under the base case scenario is HIDDEN Compared to the current market price of 1.85 USD, Talis Biomedical Corporation is HIDDEN
Current Assets | 77.7 M |
Cash & Short-Term Investments | 76.7 M |
Receivables | 50 K |
Other Current Assets | 901 K |
Non-Current Assets | 17 M |
Long-Term Investments | 1.54 M |
PP&E | 15.4 M |
Other Non-Current Assets | 0 |
Current Liabilities | 8.77 M |
Accounts Payable | 1.34 M |
Short-Term Debt | 5.76 M |
Other Current Liabilities | 1.67 M |
Non-Current Liabilities | 20.5 M |
Long-Term Debt | 16.8 M |
Other Non-Current Liabilities | 3.67 M |
Revenue | 412 K |
Cost Of Revenue | 41 K |
Gross Profit | 371 K |
Operating Expenses | 67.2 M |
Operating Income | -66.8 M |
Other Expenses | -4.81 M |
Net Income | -62 M |
Net Income | -62 M |
Depreciation & Amortization | 770 K |
Capital Expenditures | -486 K |
Stock-Based Compensation | 4.35 M |
Change in Working Capital | -3.42 M |
Others | 5.82 M |
Free Cash Flow | -53.7 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
2 months ago
Sep 06, 2024
|
Bought 37.1 K USD
|
Leonard Braden Michael
10 percent owner |
+ 25000
|
1.484 USD |
2 months ago
Sep 05, 2024
|
Bought 7.14 K USD
|
Leonard Braden Michael
10 percent owner |
+ 5100
|
1.4 USD |
2 months ago
Sep 03, 2024
|
Bought 2 K USD
|
Leonard Braden Michael
10 percent owner |
+ 500
|
4 USD |
2 months ago
Aug 30, 2024
|
Bought 642 USD
|
Leonard Braden Michael
10 percent owner |
+ 151
|
4.25 USD |
2 months ago
Aug 28, 2024
|
Bought 4.81 K USD
|
Leonard Braden Michael
10 percent owner |
+ 1215
|
3.9627 USD |
2 months ago
Aug 26, 2024
|
Bought 51.3 K USD
|
Leonard Braden Michael
10 percent owner |
+ 13167
|
3.8978 USD |
3 years ago
Nov 18, 2021
|
Bought 218 K USD
|
BAKER BROS. ADVISORS LP
director, 10 percent owner: |
+ 50000
|
4.365 USD |
3 years ago
Aug 13, 2021
|
Sell 211 K USD
|
Ramakrishnan Ramesh
|
- 27502
|
7.66 USD |
3 years ago
May 17, 2021
|
Bought 111 K USD
|
Scott Randal W.
Director |
+ 11000
|
10.11 USD |
3 years ago
May 14, 2021
|
Bought 91.4 K USD
|
Scott Randal W.
Director |
+ 9000
|
10.16 USD |
3 years ago
Feb 17, 2021
|
Bought 84.8 K USD
|
Popovits Kimberly J
Director |
+ 5300
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 5 M USD
|
Scott Randal W.
Director |
+ 312500
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 92.7 M USD
|
BAKER BROS. ADVISORS LP
director, 10 percent owner: |
+ 5792538
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 7.32 M USD
|
BAKER BROS. ADVISORS LP
director, 10 percent owner: |
+ 457462
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 16 K USD
|
Ramakrishnan Ramesh
Sr. Vice President, R&D |
+ 1000
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 1 M USD
|
Posard Matthew L.
Director |
+ 62500
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 27.2 K USD
|
Moody John Roger Jr
Chief Financial Officer |
+ 1700
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 64 K USD
|
Liu Douglas
Sr. Vice President, Operations |
+ 4000
|
16 USD |
3 years ago
Feb 17, 2021
|
Bought 32 K USD
|
Flick Karen E.
Chief of Staff, Sr. VP, Legal |
+ 2000
|
16 USD |